Skip to main content

Advertisement

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis

Fig. 3

Inhibition of ERK1/2 decreased PDAC cell viability and EMT transition. a AsPC-1, (b) SUIT-2, (c) SLMA, and (d) SLMS cell viability after 72 h; treatment with various concentrations of ERK inhibitor after. IC50 values are indicated. e Western blot of E-cadherin, vimentin, and p-ERK1/2 levels of highly metastatic cancer cells after treatment with ERK inhibitor SCH772984 at IC50 value. The indicated protein was extracted exclusively from the living adherent cells. Negative control: DMSO

Back to article page